30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

A First Look at 2010 Results: RTI Biologics

RTI BIOLOGICS
$104.3MM, +0.5%
* Spinal Constructs $33.9MM, -17%
* Sports Medicine $45.0MM, +14%
* Bone Graft Substitutes and General Orthopaedic $25.4MM, +10%

* Sports Medicine will remain key growth driver going forward
* Availability of Sports Medicine tissues somewhat dependent upon growth rates of other businesses
* Over 2011 and beyond, seeking tuck-in acquisitions to enhance Sports Medicine portfolio, leverage direct distribution
* Spine expected to be relatively flat in 2011 due to pressure from hospitals, payers
* Will expand spinal distributors during year
* Anticipates early 2012 launch for Multipotent Adult Progenitor Cell (MAPC) technologies (via exclusive agreement with Athersys), adding reps incrementally in Bone Graft segment during 2011 to support launch
* Will initiate small and large animal studies early in 2H11 for MAPC, with initial human implants in 4Q11